Supplementary Table 3 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

Authors :: Neil J. Clendeninn
Heiko Krissel
Prabhu Rajagopalan
Kimberly J. Manhard
David M. Wilson
Sonny Gunawan
Li-Tain Yeh
Zancong Shen
Jeffrey N. Miner
Cory Iverson
Diane P. Leffingwell
Lawrence Garbo
Morris Sherman
Aram F. Hezel
Joe J. Stephenson
Carlos H.R. Becerra
Fadi Braiteh
Anthony El-Khoueiry
Donald A. Richards
Alex A. Adjei
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Overview of dose-limiting toxicities and adverse events leading to discontinuation and relationship to study treatment

Tools